With its new anti-epileptic drug cenobamate now under review in Europe, Arvelle Therapeutics GmbH is doing the groundwork for the commercial launch that should turn the Swiss biotech into a fully integrated pharmaceutical company.
Earlier this month, the European Medicines Agency accepted Arvelle's marketing authorization application (MAA) for cenobamate, which is licensed from South...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
